1
|
Urso L, Lancia F, Ortolan N, Frapoli M, Rauso M, Artioli P, Cittanti C, Uccelli L, Frassoldati A, Evangelista L, Bartolomei M. 18F-Choline PET/CT or PET/MR and the evaluation of response to systemic therapy in prostate cancer: are we ready? Clin Transl Imaging 2022; 10:687-695. [PMID: 35919380 PMCID: PMC9333077 DOI: 10.1007/s40336-022-00515-7] [Citation(s) in RCA: 6] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/10/2022] [Accepted: 07/18/2022] [Indexed: 01/01/2023]
Abstract
Purpose During the last decade, [18F]F-choline positron emission tomography (PET) had a rising role in prostate cancer (PCa) imaging. However, despite auspicious premises, [18F]F-choline PET is not currently recommended for the evaluation of response to therapy assessment in PCa, mainly due to the lack of large-scale prospective trials. Methods We report the cases of seven patients affected by PCa, in which [18F]F-choline PET (either with computed tomography—CT or magnetic resonance imaging—MR) contributed significantly in the systemic therapy response evaluation. Results and conclusion [18F]F-choline PET/CT or PET/MR demonstrated to be a useful imaging modality in the assessment of response to systemic therapy in metastatic PCa patients, irrespective of the stage of disease (either in hormone sensitive and in castrate resistant condition) and the kind of systemic treatment. In most cases, PSA serum values and [18F]F-choline PET showed a synchronous disease evolution after systemic therapy. ADT can alter [18F]F-choline uptake, therefore the time of scan should be correctly planned. Finally, PET/CT with [18F]F-choline is a useful tool for reinforcing the identification of metastatic disease in case of a switch from metastatic castration sensitive to castration resistant PCa.
Collapse
Affiliation(s)
- Luca Urso
- Department of Translational Medicine, University of Ferrara, Ferrara, Italy
- Nuclear Medicine Unit, Oncological Medical and Specialists Department, University Hospital of Ferrara, Via Aldo Moro 8, 44124 Ferrara, Italy
| | - Federica Lancia
- Oncological Medical and Specialists Department, Oncology Unit, University Hospital of Ferrara, Ferrara, Italy
| | - Naima Ortolan
- Department of Translational Medicine, University of Ferrara, Ferrara, Italy
- Nuclear Medicine Unit, Oncological Medical and Specialists Department, University Hospital of Ferrara, Via Aldo Moro 8, 44124 Ferrara, Italy
| | - Marta Frapoli
- Oncological Medical and Specialists Department, Oncology Unit, University Hospital of Ferrara, Ferrara, Italy
| | - Martina Rauso
- Oncological Medical and Specialists Department, Oncology Unit, University Hospital of Ferrara, Ferrara, Italy
| | - Paolo Artioli
- Nuclear Medicine Unit, Department of Medicine, DIMED University of Padua, Padua, Italy
| | - Corrado Cittanti
- Department of Translational Medicine, University of Ferrara, Ferrara, Italy
- Nuclear Medicine Unit, Oncological Medical and Specialists Department, University Hospital of Ferrara, Via Aldo Moro 8, 44124 Ferrara, Italy
| | - Licia Uccelli
- Department of Translational Medicine, University of Ferrara, Ferrara, Italy
- Nuclear Medicine Unit, Oncological Medical and Specialists Department, University Hospital of Ferrara, Via Aldo Moro 8, 44124 Ferrara, Italy
| | - Antonio Frassoldati
- Department of Translational Medicine, University of Ferrara, Ferrara, Italy
- Oncological Medical and Specialists Department, Oncology Unit, University Hospital of Ferrara, Ferrara, Italy
| | - Laura Evangelista
- Nuclear Medicine Unit, Department of Medicine, DIMED University of Padua, Padua, Italy
| | - Mirco Bartolomei
- Nuclear Medicine Unit, Oncological Medical and Specialists Department, University Hospital of Ferrara, Via Aldo Moro 8, 44124 Ferrara, Italy
| |
Collapse
|
2
|
Oh JM, Begum HM, Liu YL, Ren Y, Shen K. Recapitulating Tumor Hypoxia in a Cleanroom-Free, Liquid-Pinning-Based Microfluidic Tumor Model. ACS Biomater Sci Eng 2022; 8:3107-3121. [PMID: 35678715 DOI: 10.1021/acsbiomaterials.2c00207] [Citation(s) in RCA: 9] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
In tumors, the metabolic demand of cancer cells often outpaces oxygen supply, resulting in a gradient of tumor hypoxia accompanied with heterogeneous resistance to cancer therapeutics. Models recapitulating tumor hypoxia are therefore essential for developing more effective cancer therapeutics. Existing in vitro models often fail to capture the spatial heterogeneity of tumor hypoxia or involve high-cost, complex fabrication/handling techniques. Here, we designed a highly tunable microfluidic device that induces hypoxia through natural cell metabolism and oxygen diffusion barriers. We adopted a cleanroom-free, micromilling-replica-molding strategy and a microfluidic liquid-pinning approach to streamline the fabrication and tumor model establishment. We also implemented a thin-film oxygen diffusion barrier design, which was optimized through COMSOL simulation, to support both two-dimensional (2-D) and three-dimensional (3-D) hypoxic models. We demonstrated that liquid-pinning enables an easy, injection-based micropatterning of cancer cells of a wide range of parameters, showing the high tunability of our design. Human breast cancer and prostate cancer cells were seeded and stained after 24 h of 2-D and 3-D culture to validate the natural induction of hypoxia. We further demonstrated the feasibility of the parallel microfluidic channel design to evaluate dual therapeutic conditions in the same device. Overall, our new microfluidic tumor model serves as a user-friendly, cost-effective, and highly scalable platform that provides spatiotemporal analysis of the hypoxic tumor microenvironments suitable for high-content biological studies and therapeutic discoveries.
Collapse
Affiliation(s)
- Jeong Min Oh
- Department of Biomedical Engineering, University of Southern California, Los Angeles, California 90089, United States
| | - Hydari Masuma Begum
- Department of Biomedical Engineering, University of Southern California, Los Angeles, California 90089, United States
| | - Yao Lucia Liu
- Department of Biomedical Engineering, University of Southern California, Los Angeles, California 90089, United States
| | - Yuwei Ren
- Department of Biomedical Engineering, University of Southern California, Los Angeles, California 90089, United States
| | - Keyue Shen
- Department of Biomedical Engineering, University of Southern California, Los Angeles, California 90089, United States.,Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, California 90033, United States.,USC Stem Cell, University of Southern California, Los Angeles, California 90033, United States
| |
Collapse
|
3
|
Gomes MC, Chen J, Cunha A, Trindade T, Zheng G, Tomé JPC. Complex cellular environments imaged by SERS nanoprobes using sugars as an all-in-one vector. J Mater Chem B 2021; 9:9285-9294. [PMID: 34709285 DOI: 10.1039/d1tb01360b] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
Raman spectroscopy coupled with confocal microscopy offers an alternative bioimaging technique overcoming limitations associated with sensitivity, tissue penetration and image resolution. Allied to the surface-enhanced Raman scattering (SERS) properties of gold nanoparticles (AuNP), we designed SERS nanoprobes with enhanced properties and straightforward application as bio-labelling agents for gliomas. The ensuing nanoprobes coated with simple sugar units (galactose or glucose) allowed assessing information about their intracellular localization (vesicular structures), with impressive sensitivity towards complex environments and proved the ability to overcome biological auto-fluorescence and high penetration in tissues. We validate the use of sugars as an all-in-one vector (Raman reporter, conferring high stability, biocompatibility and affinity to glioma cells) as imaging agents using an impressive technique.
Collapse
Affiliation(s)
- Maria C Gomes
- LAQV-REQUINTE and Department of Chemistry, University of Aveiro, 3810-193 Aveiro, Portugal.,Princess Margaret Cancer Center, University Health Network, Toronto, ON, Canada.
| | - Juan Chen
- Princess Margaret Cancer Center, University Health Network, Toronto, ON, Canada.
| | - Angela Cunha
- CESAM and Department of Biology, University of Aveiro, 3810-193 Aveiro, Portugal
| | - Tito Trindade
- CICECO-Aveiro Institute of Materials and Department of Chemistry, University of Aveiro, 3810-193 Aveiro, Portugal
| | - Gang Zheng
- Princess Margaret Cancer Center, University Health Network, Toronto, ON, Canada. .,Department of Medical Biophysics, University of Toronto, Toronto, ON, Canada
| | - João P C Tomé
- LAQV-REQUINTE and Department of Chemistry, University of Aveiro, 3810-193 Aveiro, Portugal.,CQE and Departamento de Engenharia Química, Instituto Superior Técnico, Universidade de Lisboa, 1049-001 Lisboa, Portugal.
| |
Collapse
|
4
|
Luining WI, Meijer D, Dahele MR, Vis AN, Oprea-Lager DE. Nuclear Imaging for Bone Metastases in Prostate Cancer: The Emergence of Modern Techniques Using Novel Radiotracers. Diagnostics (Basel) 2021; 11:diagnostics11010117. [PMID: 33450817 PMCID: PMC7828280 DOI: 10.3390/diagnostics11010117] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/30/2020] [Revised: 01/06/2021] [Accepted: 01/11/2021] [Indexed: 12/25/2022] Open
Abstract
Accurate staging of prostate cancer (PCa) at initial diagnosis and at biochemical recurrence is important to determine prognosis and the optimal treatment strategy. To date, treatment of metastatic PCa has mostly been based on the results of conventional imaging with abdominopelvic computed tomography (CT) and bone scintigraphy. However, these investigations have limited sensitivity and specificity which impairs their ability to accurately identify and quantify the true extent of active disease. Modern imaging modalities, such as those based on the detection of radioactively labeled tracers with combined positron emission tomography/computed tomography (PET/CT) scanning have been developed specifically for the detection of PCa. Novel radiotracers include 18F-sodium fluoride (NaF), 11C-/18F-fluorocholine (FCH), 18F-fluordihydrotestosterone (FDHT), 68Gallium and 18F-radiolabeled prostate-specific membrane antigen (e.g., 68Ga-PSMA-11, 18F-DCFPyL). PET/CT with these tracers outperforms conventional imaging. As a result of this, although their impact on outcome needs to be better defined in appropriate clinical trials, techniques like prostate-specific membrane antigen (PSMA) PET/CT have been rapidly adopted into clinical practice for (re)staging PCa. This review focuses on nuclear imaging for PCa bone metastases, summarizing the literature on conventional imaging (focusing on CT and bone scintigraphy—magnetic resonance imaging is not addressed in this review), highlighting the prognostic importance of high and low volume metastatic disease which serves as a driver for the development of better imaging techniques, and finally discussing modern nuclear imaging with novel radiotracers.
Collapse
Affiliation(s)
- Wietske I. Luining
- Department of Urology, Prostate Cancer Network Netherlands, Amsterdam University Medical Center, VU University, 1081 HV Amsterdam, The Netherlands; (D.M.); (A.N.V.)
- Department of Radiology & Nuclear Medicine, Cancer Center Amsterdam, Amsterdam University Medical Center, VU University, 1081 HV Amsterdam, The Netherlands;
- Correspondence: ; Tel.: +31-20-4443289; Fax: +31-20-4446031
| | - Dennie Meijer
- Department of Urology, Prostate Cancer Network Netherlands, Amsterdam University Medical Center, VU University, 1081 HV Amsterdam, The Netherlands; (D.M.); (A.N.V.)
- Department of Radiology & Nuclear Medicine, Cancer Center Amsterdam, Amsterdam University Medical Center, VU University, 1081 HV Amsterdam, The Netherlands;
| | - Max R. Dahele
- Department of Radiation Oncology, Cancer Center Amsterdam, Amsterdam University Medical Center, VU University Amsterdam, 1081 HV Amsterdam, The Netherlands;
| | - André N. Vis
- Department of Urology, Prostate Cancer Network Netherlands, Amsterdam University Medical Center, VU University, 1081 HV Amsterdam, The Netherlands; (D.M.); (A.N.V.)
| | - Daniela E. Oprea-Lager
- Department of Radiology & Nuclear Medicine, Cancer Center Amsterdam, Amsterdam University Medical Center, VU University, 1081 HV Amsterdam, The Netherlands;
| |
Collapse
|
5
|
Qualitative and quantitative reproducibility of [18]fluoromethycholine PET/computed tomography in prostate cancer. Nucl Med Commun 2020; 41:147-154. [PMID: 31939917 DOI: 10.1097/mnm.0000000000001129] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Abstract
BACKGROUND Recurrence occurs in more than 50% of prostate cancer. To be effective, treatments require precise localization of tumor cells. [F]fluoromethylcholine ([18F]FCH) PET/computed tomography (CT) is currently used to restage disease in cases of biochemical relapse. To be used for therapy response as has been suggested, repeatability limits of PET derived indices need to be established. OBJECTIVE The aim of our study was to prospectively assess the qualitative and quantitative reproducibility [18F]FCH PET/CT in prostate cancer. METHODS Patients with histologically proven prostate cancer referred for initial staging or restaging were prospectively included. All patients underwent two [18F]FCH PET/CTs in the same conditions within a maximum of 3 weeks' time. We studied the repeatability of the visual report and the repeatability of SUVmax and its evolution over the acquisition time in lesions, liver and vascular background. Statistical analysis was performed using the Bland-Altman approach. RESULTS Twenty-one patients were included. Reporting repeatability was excellent with 97.8% of concordance. Mean repeatability of SUVmax considering all times and all lesions was 2.2% ± 20. Evolution of SUVmax was unpredictable, either increasing or decreasing over the acquisition time, both for lesions and for physiological activity. CONCLUSION Our study demonstrated that visual report of [18F]FCH PET/CT was very reproducible and that the repeatability limits of SUVmax was similar to those of other PET radiotracers. An SUVmax difference of more than 40% should be considered as representing a treatment response effect. Change of SUVmax during the acquisition time varied and should not be considered as an interpretation criterion.
Collapse
|
6
|
Ermert J, Benešová M, Hugenberg V, Gupta V, Spahn I, Pietzsch HJ, Liolios C, Kopka K. Radiopharmaceutical Sciences. Clin Nucl Med 2020. [DOI: 10.1007/978-3-030-39457-8_2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
7
|
Vija Racaru L, Sinigaglia M, Kanoun S, Ben Bouallègue F, Tal I, Brillouet S, Bauriaud-Mallet M, Zerdoud S, Dierickx L, Vallot D, Caselles O, Gabiache E, Pascal P, Courbon F. Fluorine-18-fluorocholine PET/CT parameters predictive for hematological toxicity to radium-223 therapy in castrate-resistant prostate cancer patients with bone metastases: a pilot study. Nucl Med Commun 2018; 39:672-679. [PMID: 29790867 PMCID: PMC6023601 DOI: 10.1097/mnm.0000000000000850] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/07/2018] [Revised: 03/30/2018] [Accepted: 03/31/2018] [Indexed: 01/17/2023]
Abstract
PURPOSE This study aims to predict hematological toxicity induced by Ra therapy. We investigated the value of metabolically active bone tumor volume (MBTV) and total bone lesion activity (TLA) calculated on pretreatment fluorine-18-fluorocholine (F-FCH) PET/CT in castrate-resistant prostate cancer (CRPC) patients with bone metastases treated with Ra radionuclide therapy. PATIENTS AND METHODS F-FCH PET/CT imaging was performed in 15 patients with CRPC before treatment with Ra. Bone metastatic disease was quantified on the basis of the maximum standardized uptake value (SUV), total lesion activity (TLA=MBTV×SUVmean), or MBTV/height (MBTV/H) and TLA/H. F-FCH PET/CT bone tumor burden and activity were analyzed to identify which parameters could predict hematological toxicity [on hemoglobin (Hb), platelets (PLTs), and lymphocytes] while on Ra therapy. Pearson's correlation was used to identify the correlations between age, prostate-specific antigen, and F-FCH PET parameters. RESULTS MBTV ranged from 75 to 1259 cm (median: 392 cm). TLA ranged from 342 to 7198 cm (median: 1853 cm). Patients benefited from two to six cycles of Ra (n=56 cycles in total). At the end of Ra therapy, five of the 15 (33%) patients presented grade 2/3 toxicity on Hb and lymphocytes, whereas three of the 15 (20%) patients presented grade 2/3 PLT toxicity.Age was correlated negatively with both MBTV (r=-0.612, P=0.015) and TLA (r=-0.596, P=0.018). TLA, TLA/H, and MBTV/H predicted hematological toxicity on Hb, whereas TLA/H and MBTV/H predicted toxicity on PLTs at the end of Ra cycles. Receiver operating characteristic curve analysis allowed to define the cutoffs for MBTV (915 cm) and TLA (4198 cm) predictive for PLT toxicity, with an accuracy of 0.92 and 0.99. CONCLUSION Tumor bone burden calculation is feasible with F-FCH PET/CT with freely available open-source software. In this pilot study, baseline F-FCH PET/CT markers (TLA, MBTV) have shown abilities to predict Hb and PLT toxicity after Ra therapy and could be explored for patient selection and treatment optimization.
Collapse
Affiliation(s)
- Lavinia Vija Racaru
- Department of Nuclear Medicine, Claudius Regaud Institute, Toulouse Oncology University Institute-IUCT-Oncopole
- Department of Biophysics and Nuclear Medicine, Faculty of Medicine, Paul Sabatier University
- INSERM U1037, Toulouse Oncology Research Centre (Centre de recherches en cancérologie de Toulouse, CRCT)
| | - Mathieu Sinigaglia
- Department of Nuclear Medicine, Claudius Regaud Institute, Toulouse Oncology University Institute-IUCT-Oncopole
| | - Salim Kanoun
- Department of Nuclear Medicine, Claudius Regaud Institute, Toulouse Oncology University Institute-IUCT-Oncopole
| | | | - Ilan Tal
- IT Department, Beth Israel Deaconess Medical Center, Haifa, Israel
| | - Sévérine Brillouet
- Department of Nuclear Medicine, Claudius Regaud Institute, Toulouse Oncology University Institute-IUCT-Oncopole
- INSERM U1037, Toulouse Oncology Research Centre (Centre de recherches en cancérologie de Toulouse, CRCT)
| | - Mathilde Bauriaud-Mallet
- Department of Nuclear Medicine, Claudius Regaud Institute, Toulouse Oncology University Institute-IUCT-Oncopole
- INSERM U1037, Toulouse Oncology Research Centre (Centre de recherches en cancérologie de Toulouse, CRCT)
| | - Slimane Zerdoud
- Department of Nuclear Medicine, Claudius Regaud Institute, Toulouse Oncology University Institute-IUCT-Oncopole
| | - Lawrence Dierickx
- Department of Nuclear Medicine, Claudius Regaud Institute, Toulouse Oncology University Institute-IUCT-Oncopole
| | - Delphine Vallot
- Department of Nuclear Medicine, Claudius Regaud Institute, Toulouse Oncology University Institute-IUCT-Oncopole
| | - Olivier Caselles
- Department of Nuclear Medicine, Claudius Regaud Institute, Toulouse Oncology University Institute-IUCT-Oncopole
| | - Erwan Gabiache
- Department of Nuclear Medicine, Claudius Regaud Institute, Toulouse Oncology University Institute-IUCT-Oncopole
| | - Pierre Pascal
- Department of Nuclear Medicine, Claudius Regaud Institute, Toulouse Oncology University Institute-IUCT-Oncopole
- Department of Nuclear Medicine, Toulouse University Hospitals, Toulouse, France
| | - Frederic Courbon
- Department of Nuclear Medicine, Claudius Regaud Institute, Toulouse Oncology University Institute-IUCT-Oncopole
- Department of Biophysics and Nuclear Medicine, Faculty of Medicine, Paul Sabatier University
- INSERM U1037, Toulouse Oncology Research Centre (Centre de recherches en cancérologie de Toulouse, CRCT)
- Department of Nuclear Medicine, Toulouse University Hospitals, Toulouse, France
| |
Collapse
|
8
|
Lange R, ter Heine R, van Wieringen WN, Tromp AM, Paap M, Bloemendal HJ, de Klerk JMH, Hendrikse NH, Geldof AA. Cytotoxic Effects of the Therapeutic Radionuclide Rhenium-188 Combined with Taxanes in Human Prostate Carcinoma Cell Lines. Cancer Biother Radiopharm 2017; 32:16-23. [PMID: 28118029 DOI: 10.1089/cbr.2016.2129] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/17/2023] Open
Abstract
OBJECTIVE Rhenium-188-HEDP is an effective radiopharmaceutical for the treatment of painful bone metastases from prostate cancer. The effectiveness of the β-radiation emitted by 188Re might be enhanced by combination with chemotherapy, using the radiosensitization concept. Therefore, the authors investigated the combined treatment of the taxanes, docetaxel and cabazitaxel, with 188Re in prostate carcinoma cell lines. MATERIALS AND METHODS The cytotoxic effects of single and combined treatment with taxanes and 188Re were investigated in three human prostate carcinoma cell lines (PC-3, DU 145, and LNCaP), using the colony-forming assay. The half maximal effective concentration (EC50) of all individual agents was determined. The combined treatment was studied at 0.25, 0.5, 1, 2, and 4 times the EC50 of each agent. The interaction was investigated with a regression model. RESULTS The survival curves showed dose-dependent cell growth inhibition for both the taxanes and 188Re. The regression model showed a good capability of explaining the data. It proved additivity in all combination experiments and confirmed a general trend to a slight subadditive effect. CONCLUSIONS This proof-of-mechanism study exploring radiosensitization by combining 188Re and taxanes showed no synergism, but significant additivity. This encourages the design of in vivo studies. Future research should explore the potential added value of concomitant treatment of bone metastases with chemotherapy and 188Re-HEDP.
Collapse
Affiliation(s)
- Rogier Lange
- 1 Department of Clinical Pharmacy, Meander Medical Center , Amersfoort, The Netherlands
| | - Rob ter Heine
- 2 Department of Pharmacy, Radboud University Medical Center , Nijmegen
| | - Wessel N van Wieringen
- 3 Department of Epidemiology and Biostatistics, VU University Medical Center , Amsterdam, The Netherlands .,4 Department of Mathematics, VU University , Amsterdam, The Netherlands
| | - Adrienne M Tromp
- 5 Department of Pharmaceutical Sciences, Utrecht University , Utrecht, The Netherlands
| | - Mayke Paap
- 5 Department of Pharmaceutical Sciences, Utrecht University , Utrecht, The Netherlands
| | - Haiko J Bloemendal
- 6 Department of Internal Medicine/Medical Oncology, Meander Medical Center , Amersfoort, The Netherlands .,7 Department of Medical Oncology, University Medical Center , Utrecht, The Netherlands
| | - John M H de Klerk
- 8 Department of Nuclear Medicine, Meander Medical Center , Amersfoort, The Netherlands
| | - N Harry Hendrikse
- 9 Department of Clinical Pharmacology and Pharmacy, VU University Medical Center , Amsterdam, The Netherlands .,10 Department of Radiology and Nuclear Medicine, VU University Medical Center , Amsterdam, The Netherlands
| | - Albert A Geldof
- 11 Department of Urology, VU University Medical Center , Amsterdam, The Netherlands .,12 Department of Radiology and Nuclear Medicine, VU University Medical Center , Amsterdam, The Netherlands
| |
Collapse
|
9
|
Lee J, Sato MM, Coel MN, Lee KH, Kwee SA. Prediction of PSA Progression in Castration-Resistant Prostate Cancer Based on Treatment-Associated Change in Tumor Burden Quantified by 18F-Fluorocholine PET/CT. J Nucl Med 2016; 57:1058-64. [PMID: 26912444 DOI: 10.2967/jnumed.115.169177] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/24/2015] [Accepted: 01/26/2016] [Indexed: 01/19/2023] Open
Abstract
UNLABELLED Measurements of metabolically active tumor volume (MATV) can be applied to (18)F-fluorocholine PET/CT to quantify whole-body tumor burden. This study evaluated the serial application of these measurements as systemic treatment response markers and predictors of disease progression in patients with castration-resistant prostate cancer (CRPC). METHODS Forty-two patients completed sequential (18)F-fluorocholine PET/CT scans before and 1-3 mo after starting treatment for CRPC. Whole-body tumor segmentation was applied to determine net MATV from each scan. Changes in net MATV were evaluated as predictors of time to prostate-specific antigen (PSA) progression by Kaplan-Meier and proportional hazards regression analysis. RESULTS Treatments consisted of chemotherapy in 16 patients, antiandrogens in 19 patients, (223)Ra-dichloride in 5 patients, and sipuleucel-T in 2 patients. A significant MATV response (defined as a ≥30% decrease in net MATV) was observed in 20 patients on the basis of in-treatment PET/CT performed an average of 51 d (median, 49 d) into treatment. Significantly longer times to PSA progression were observed in patients who exhibited an MATV response (418 d vs. 116 d, P = 0.0067). MATV response was associated with a hazard ratio of 0.246 (P = 0.0113) for PSA progression, which remained significant when adjusted for treatment type. CONCLUSION Significant changes in whole-body tumor burden can be measured on (18)F-fluorocholine PET/CT over the course of contemporary treatments for CRPC. In this study, these changes were found to be predictive of PSA progression as a potential surrogate marker of treatment outcome. Because (18)F-fluorocholine PET/CT can also be used for localizing resistant tumors, this modality can potentially complement other measures of response in the precision management of advanced prostate cancer.
Collapse
Affiliation(s)
- Joohee Lee
- Oncology Research Program, Queen's Medical Center, Honolulu, Hawaii Department of Nuclear Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea
| | - Miles M Sato
- Oncology Research Program, Queen's Medical Center, Honolulu, Hawaii
| | - Marc N Coel
- Hamamatsu/Queen's PET Imaging Center, Queen's Medical Center, Honolulu, Hawaii; and
| | - Kyung-Han Lee
- Department of Nuclear Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea
| | - Sandi A Kwee
- Hamamatsu/Queen's PET Imaging Center, Queen's Medical Center, Honolulu, Hawaii; and Department of Medicine, John A. Burns School of Medicine, University of Hawaii, Honolulu, Hawaii
| |
Collapse
|
10
|
Oprea-Lager DE, Kramer G, van de Ven PM, van den Eertwegh AJ, van Moorselaar RJ, Schober P, Hoekstra OS, Lammertsma AA, Boellaard R. Repeatability of Quantitative 18F-Fluoromethylcholine PET/CT Studies in Prostate Cancer. J Nucl Med 2015; 57:721-7. [DOI: 10.2967/jnumed.115.167692] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/02/2015] [Accepted: 12/01/2015] [Indexed: 11/16/2022] Open
|